Folotyn (pralatrexate)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- pralatrexate
- Company
- Allos Therapeutics Ltd
- Status
- Refused
- Therapeutic area
- Lymphoma, T-Cell
- CHMP opinion
- Thu 19 Apr 2012
- Designations
- Orphan
- Application
- EMEA/H/C/002096
- ATC
- L01BA05
- Official record
- www.ema.europa.eu
Indication
treatment of peripheral T-cell lymphoma
Regulatory milestones
No milestones recorded in the last year.
Follow Folotyn
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.